modelV09IX14
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Gallium68gaGozetotide | |
| ATC code: | V09IX14 | route: | intravenous |
| compartments: | 1 | |
| dosage: | 150 | mg |
| volume of distribution: | 0.16 | L |
| clearance: | 0.096 | L/h/kg |
| other parameters in model implementation | ||
Gallium (68Ga) gozetotide, also known as 68Ga-PSMA-11, is a radiopharmaceutical agent used in positron emission tomography (PET) imaging for the detection of prostate-specific membrane antigen (PSMA) expressing prostate cancer lesions. It is approved for diagnostic purposes in patients with prostate cancer and is not used for therapeutic applications.
Pharmacokinetics
Pharmacokinetic parameters in adult male patients with prostate cancer, healthy renal and hepatic function, following single intravenous administration for diagnostic PET imaging.
References
Inaki, A, et al., & Kinuya, S (2024). Evaluation of . Annals of nuclear medicine 38(8) 587–595. DOI:10.1007/s12149-024-01931-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38750331
Olde Heuvel, J, et al., & Stokkel, MPM (2021). Early differences in dynamic uptake of 68Ga-PSMA-11 in primary prostate cancer: A test-retest study. PloS one 16(2) e0246394–None. DOI:10.1371/journal.pone.0246394 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33529259
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)